Fig. 1
From: A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
a Overall survival. Kaplan Meier survival curves of patients treated with LY2603618/gemcitabine combination therapy compared with historical gemcitabine studies. [1Jänne PA, Paz-Ares L, Oh Y, Eschbach C, Hirsh V, Enas N, Brail L, von Pawel J. Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer. J Thorac Oncol. 2014;9:126–31. 2Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmerman A, John W, Von Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639–45.] b Progression-free survival. Kaplan Meier survival curves of patients treated with LY2603618/gemcitabine compared with gemcitabine monotherapy